Jo Ginderachter Myeloid Cell Immunology Laboratory, Vrije Universiteit Brussel (VIB), Belgium, Belgium,
3 protocols

Jiri Keirsse Myeloid Cell Immunology Laboratory, Vrije Universiteit Brussel (VIB), Belgium, Belgium,
3 protocols

Chloé Abels Myeloid Cell Immunology Laboratory, Vrije Universiteit Brussel (VIB), Belgium, Belgium,
2 protocols

Eva Overmeire Myeloid Cell Immunology Laboratory, Belgium, Belgium,
2 protocols

Damya Laoui
  • VIB-Vrije Universiteit Brussl, Belgium
  • 2 Author merit

Education

PhD, Vrije Universiteit Brussel, Belgium, 2014

Current position

Research professor, Cellular and Molecular Immunology, VIB-VUB, Belgium

Publications

  1. Clappaert EJ, Murgaski A, Van Damme H, Kiss M, Laoui D. Diamonds in the rough: Harnessing tumor-associated 2018 myeloid cells for cancer therapy. Frontiers Immunol, 2018 Oct 8;9:2250. (IF: 5,551).
  2. Kiss M, Van Gassen S, Movahedi K, Saeys Y, Laoui D. Myeloid cell heterogeneity in cancer: not a single cell alike. 2018 Cellular Immunology, 2018 Aug;330:188-201 (IF: 3,172).
  3. Bonelli S, Geeraerts X, Bolli E, Keirsse J, Kiss M, Pombo Antunes AR, Van Damme H, De Vlaminck K, Movahedi K, 2017 Laoui D, Raes G, Van Ginderachter JA. Beyond the M-CSF receptor: novel therapeutic targets in tumor-associated macrophages. FEBS J. 2017 Aug 20. (IF: 3,902).
  4. Farro G, Stakenborg M, Gomez-Pinilla PJ, Labeeuw E, Goverse G, Giovangiulio MD, Stakenborg N, Meroni E, D'Errico 2017 F, Elkrim Y, Laoui D, Lisowski ZM, Sauter KA, Hume DA, Van Ginderachter JA, Boeckxstaens GE, Matteoli G. CCR2-dependent monocyte-derived macrophages resolve inflammation and restore gut motility in postoperative ileus. Gut. 2017 Jun 14. (IF: 16,6).
  5. Schmittnaegel M, Rigamonti N, Kadioglu E, Cassará A, Wyser Rmili C, Kiialainen A, Kienast Y, Mueller HJ, Ooi CH, 2017 Laoui D, De Palma M. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med. 2017 Apr 12;9(385). (IF: 16, 264).
  6. Keirsse J, Van Damme H, Van Ginderachter JA, Laoui D. Exploiting tumor-associated dendritic cell heterogeneity for 2017 novel cancer therapies. J Leukoc Biol. 2017 Apr 7. (IF: 4,165)
  7. Bolli E, Movahedi K, Laoui D, Van Ginderachter JA. Novel insights in the regulation and function of macrophages in the 2017 tumor microenvironment. Curr Opin Oncol, 2017 Jan;29(1):55-61. (IF:4,614).
  8. Laoui D*, Keirsse J*, Morias Y, Van Overmeire E, Geeraerts X, Elkrim Y, Kiss M, Bolli E, Lahmar Q, Sichien D, Serneels 2016 J, Scott CL, Boon L, De Baetselier P, Mazzone M, Guilliams M§, Ginderachter JA§. *Equal contribution, §Shared senior authorship. The tumor microenvironment harbors ontogenically distinct dendritic cell populations with opposing effects on tumor immunity. Nature Communications, 2016 Dec 23;7:13720. (IF: 11, 329)
  9. Baer C*, Squadrito MS*, Laoui D, Thompson D, Hansen SK, Kiialainen A, Hoves S, Ries CH, Ooi CH, De Palma M. 2016 *Equal contribution. Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumor immunity. Nat Cell Biol. 2016 Jul;18(7):790-802. (IF: 18,398).
  10. Van Overmeire E, Stijlemans B, Heymann F, Keirsse J, Morias Y, Elkrim Y, Brys L, Abels C, Lahmar Q, Ergen C, 2016 Vereecke L, Tacke F, De Baetselier P, Van Ginderachter JA*, Laoui D*. *Shared senior authorship. M-CSF and GM-CSF receptor signaling differentially regulate monocyte maturation and macrophage polarization in the tumor microenvironment. Cancer Res. 2016 Jan 1;76(1):35-42. (IF: 9,329).
  11. Lahmar Q, Keirsse J*, Laoui D*, Movahedi K*, Van Overmeire E*, Van Ginderachter JA. Tissue-resident versus 2016 monocyte-derived macrophages in the tumor microenvironment. *Equal contribution. Biochim Biophys Acta. 2016 Jan;1865(1):23-34. (IF:4,381).
  12. Blykers A, Schoonooghe S, Xavier C, D'hoe K, Laoui D, D'Huyvetter M, Vaneycken I, Cleeren F, Bormans G, 2015 Heemskerk J, Raes G, De Baetselier P, Lahoutte T, Devoogdt N, Van Ginderachter JA, Caveliers V. PET imaging of Macrophage Mannose Receptor-expressing macrophages in tumor stroma using 18F-radiolabeled Camelid single-domain antibody fragments. J Nucl Med. 2015 Aug;56(8):1265-71. (IF: 6,160)
  13. Van den Bossche J, Laoui D, Naessens T, Smits HH, Hokke CH, Stijlemans B, Grooten J, De Baetselier P, Van 2015 Ginderachter JA. E-cadherin expression in macrophages dampens their inflammatory responsiveness in vitro, but does not modulate M2-regulated pathologies in vivo. Sci Rep. 2015 Jul 31;5:12599. (IF: 5,578).
  14. Morias Y*, Abels C*, Laoui D, Van Overmeire E, Guilliams M, Schouppe E, Tacke F, deVries CJ, De Baetselier P, 2015 Beschin A. *Equal contribution. Ly6C- Monocytes Regulate Parasite-Induced Liver Inflammation by Inducing the Differentiation of Pathogenic Ly6C+ Monocytes into Macrophages. PLoS Pathog. 2015 May 28;11(5):e1004873. (IF: 8,057).
  15. Keirsse Jiri, Laoui Damya, Van Overmeire Eva, Van Ginderachter Jo A. Targeting Cell-Intrinsic and Cell-Extrinsic 2014 Mechanisms of Intravasation in Invasive Breast Cancer. Science Signaling. 2014 Nov 25;7(353):pe28. (IF: 6.337)
  16. Chittezhath M, Dhillon MK, Lim JY, Laoui D, Shalova IN, Teo Y, Chen J, Kamaraj R, Raman L, Lum J, Thamboo TP, 2014 Chiong E, Zolezzi F, Yang H, Van Ginderachter JA, Poidinger M, Wong ASC and Biswas SK. Molecular profiling reveals a tumor promoting phenotype of monocytes and macrophages in human cancer progression. Immunity, 2014, In Press. (IF: 19,748). 
  17. Laoui D, Van Overmeire E, De Baetselier P, Van Ginderachter JA, Raes G. Functional Relationship between Tumor- 2014 Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression. Front Immunol. 2014 Oct 7;5:489. 
  18. Van Overmeire E, Laoui D, Keirsse J, Bonelli S, Lahmar Q, Van Ginderachter JA. STAT of the union: dynamics of 2014 distinct tumor-associated macrophage subsets governed by STAT1. Eur J Immunol. 2014 Aug;44(8):2238-42.(IF: 4,970) 
  19. Van Overmeire E, Laoui D, Keirsse J, Van Ginderachter JA, Sarukhan A. Mechanisms driving macrophage diversity and 2014 specialization in distinct tumor microenvironments and parallelisms with other tissues. Front Immunol. 2014 Mar 26;5:127. 
  20. Nikolaou A, Stijlemans B, Laoui D, Schouppe E, Tran HT, Tourwé D, Chai SY, Vanderheyden PM*, Van Ginderachter 2014 JA*. *Equal contribution. Presence and regulation of insulin-regulated aminopeptidase in mouse macrophages. J. Renin-Angiotensin-Aldosterone Syst, 2014 Feb 14. (IF: 2,286).
  21. Van Overmeire E, Laoui D, Keirsse J, Van Ginderachter JA. Hypoxia and tumor-associated macrophages: A deadly 2014 alliance in support of tumor progression. OncoImmunology, 2014 Jan 1;3(1):e27561. (IF: 6,283).
  22. Laoui D, Van Overmeire E, Di Conza G, Aldeni C, Keirsse J, Morias Y, Movahedi K, Houbracken I, Schouppe E, Elkrim 2014 Y, Karroum O, Jordan B, Carmeliet P, Gysemans C, Baetselier PD, Mazzone M, Van Ginderachter JA. Tumor Hypoxia Does Not Drive Differentiation of Tumor-Associated Macrophages but Rather Fine-Tunes the M2-like Macrophage
    Population. Cancer Res. 2013 Dec 10. (IF: 9,284).
  23. Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M, Deschoemaeker S, Van Ginderachter JA, 2013 Tamagnone L, Mazzone M. Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity. Cancer Cell. 2013 Dec 9;24(6):695-709. (IF: 24,755).
  24. Schouppe E, Van Overmeire E, Laoui D, Keirsse J, Van Ginderachter JA. Modulation of CD8(+) T-cell activation events 2013 by monocytic and granulocytic myeloid-derived suppressor cells. Immunobiology. 2013 Nov;218(11):1385-91. (IF: 2,814).
  25. Schouppe E, Mommer C, Movahedi K, Laoui D, Morias Y, Gysemans C, Luyckx A, De Baetselier P, Van Ginderachter 2013 JA. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8(+) T-cell activation events. Eur J Immunol. 2013 Nov;43(11):2930-42. (IF: 4,970).
  26. Laoui D, Van Overmeire E, Van Ginderachter JA. Unsuspected allies: chemotherapy teams up with immunity to fight 2013 cancer. Eur J Immunol. 2013 Oct;43(10):2538-42. (IF: 4,970).
  27. Schoonooghe S, Laoui D, Van Ginderachter JA, Devoogdt N, Lahoutte T, De Baetselier P§, Raes G§. §Shared senior 2012 authorship. Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer. Immunobiology. 2012 Dec;217(12):1266-72. (IF: 2,814).
  28. Pello OM, Chèvre R*, Laoui D*, De Juan A, Lolo F, Andrés-Manzano MJ, Serrano M, Van Ginderachter JA, Andrés V. 2012 *Equal contribution. In vivo inhibition of c-MYC in myeloid cells impairs tumor-associated macrophage maturation and pro-tumoral activities. Plos One, 2012;7(9):e45399. (IF: 3,730).
  29. Movahedi K*, Schoonooghe S*, Laoui D*, Houbracken I, Waelput W, Breckpot K, Bouwens L, Lahoutte T, De Baetselier 2012 P, Raes G§, Devoogdt N§, Van Ginderachter JA§. *Equal contribution, §Shared senior authorship. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 2012 Aug 15;72(16):4165-77 (IF: 8.650).
  30. Van den Bossche J, Laoui D, Morias Y, Movahedi K, Raes G, De Baetselier P, Van Ginderachter JA. Claudin-1, claudin- 2012 2 and claudin-11 genes differentially associate with distinct types of anti-inflammatory macrophages in vitro and with parasite- and tumor-elicited macrophages in vivo. Scand J Immunol. 2012 Jan 23 (IF: 2,199).
  31. Laoui D, Movahedi K, Van Overmeire E, Van den Bossche J, Schouppe E, Mommer C, Nikolaou A, Morias Y, De 2011 Baetselier P, Van Ginderachter JA. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol. 2011;55(7-9):861-7 (IF: 2.823).
  32. Laoui D, Van Overmeire E, Movahedi K, Van den Bossche J, Schouppe E, Mommer C, Nikolaou A, Morias Y, De 2011 Baetselier P, Van Ginderachter JA. Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology. 2011 Nov;216(11):1192-202 (IF: 3,205).
  33. Rolny C*, Mazzone M*, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, Costa S, 2011 Vinckier S, Dresselaer T, Åkerud P, De Mol M, Salomäki H, Phillipson M, Wyns S, Larsson E, Buysschaert I, Botling J, Himmelreich U, Van Ginderachter JA, De Palma M, Dewerchin M, Claesson-Welsh L§, Carmeliet P§. *Equal contribution, §Shared senior authorship. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 2011 Jan 18;19(1):31-44 (IF: 26.566).
  34. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De 2010 Baetselier P, Van Ginderachter JA. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Research 2010 Jul 15;70(14):5728-39. (IF: 8.234).
2 Protocols published
Adoptive Transfer of Monocytes Sorted from Bone Marrow
Authors:  Damya Laoui, Eva Van Overmeire, Chloé Abels, Jiri Keirsse and Jo A Van Ginderachter, date: 01/05/2019, view: 227, Q&A: 0
Inflammatory Ly6Chi monocytes can give rise to distinct mononuclear myeloid cells in the tumor microenvironment, such as monocytic myeloid-derived suppressor cells (Mo-MDSC), immature macrophages, M2-like tumor-associated macrophages ...
Purification of Tumor-Associated Macrophages (TAM) and Tumor-Associated Dendritic Cells (TADC)
Authors:  Damya Laoui, Eva Van Overmeire, Jiri Keirsse, Kiavash Movahedi and Jo A Van Ginderachter, date: 11/20/2014, view: 15115, Q&A: 1
Tumors are heterogeneous microenvironments where complex interactions take place between neoplastic cells and infiltrating inflammatory cells, such as tumor-associated macrophages (TAM) and tumor-associated dendritic cells (TADC). The relevance of ...
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.